secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apyx Medical Corp (APYX)
CIK:        0000719135
Form:       8-K
Filed at:   2025-04-29T23:59:59+00:00
Accession:  0001437749-25-013413
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apyx Medical announces two peer-reviewed studies on Renuvion in body contouring showing safety and efficacy
--------------------------------------------------------------------------------

- First prospective RCT (Barone, 76 patients) shows Renuvion improves abdominal skin laxity and satisfaction scores vs lipoabdominoplasty alone.
- Second retrospective study (Vanek, 77 patients) finds no significant increase in complications with Renuvion despite longer surgical times.
- CEO cites >15M patients on GLP-1 drugs as growth driver; Renuvion is only FDA-cleared device for post-liposuction skin laxity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/719135/000143774925013413/0001437749-25-013413-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/719135/000143774925013413/apyx20250428_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-013413

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer